Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study
description
Transcript of Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study
![Page 1: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/1.jpg)
J. Timmer-Bonte, B. Biesma, J. Smit, F. Wilschut, J. Akkermans, T. de Boo, G. Bootsma, V. Tjan-Heijnen
• Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study
![Page 2: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/2.jpg)
Invloed van micrometastasen op “adjuvante behandeling” bij het mammacarcinoom
Dr. Vivianne Tjan-Heijneninternist-oncoloog
UMC St Radboud, Nijmegen
![Page 3: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/3.jpg)
NVMO, 19 november 2004
Micrometastase
•De definitie
•PA protocol
•Prognostisch van belang ?
•Adjuvante systeemtherapie
•Aanvullende okselklierdissectie (OKD)
![Page 4: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/4.jpg)
NVMO, 19 november 2004
Micrometastase: de oude situatie
•Zelden (IKO): 5%
•Definitie:
•was pN1a: < 2.0 mm
•maar in PA-verslag vaak alleen pN1
•dús synoniem voor N+
•dús indicatie voor adjuvante therapie
![Page 5: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/5.jpg)
NVMO, 19 november 2004
Echter, toen …. kwam de schildwachtklierprocedure
•OKD: H&E van 1 of 2 coupes
•SWK: tenminste 3 levels
H&E en IHC
Veranderd PA protocol
![Page 6: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/6.jpg)
NVMO, 19 november 2004
‘Positieve’ schildwachtklier
•Een enkele losse cel
•Groepje cellen in sinus
•Groepje cellen in parenchym
•Vele groepjes cellen in
parenchym
![Page 7: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/7.jpg)
NVMO, 19 november 2004
Behoefte aan een
betere definitie +
goede afspraken
![Page 8: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/8.jpg)
NVMO, 19 november 2004
Definitie
TNM
•H&E versus IHC
•Histologisch kenmerken:
•Proliferatie
•Invasie in parenchym
•Stroma reactie
•Grootte van metastase
![Page 9: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/9.jpg)
NVMO, 19 november 2004
TNM classificatie
Macro-metastase pN1abc/3abc > 2.0 mm
Micro-metastase pN1mi > 0.2 - < 2.0 mm
Geisoleerde tumorcel pN0(i+) < 0.2 mm
Geen pN0(i-)
![Page 10: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/10.jpg)
NVMO, 19 november 2004
Term micrometastase is misleidend
Grootte metastase:
> 0.2- < 2.0 mm
![Page 11: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/11.jpg)
NVMO, 19 november 2004
Take Home Message
Gebruik de juiste TNM definitie:
1.In de PA verslaglegging
2.Voor verdere behandeling
3.Voor interpretatie literatuur
![Page 12: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/12.jpg)
NVMO, 19 november 2004
Take Home Message
Ken het protocol op basis waarvan de patholoog
in uw ziekenhuis de SWK beoordeeld:
Aantal niveau’s +/- IHC
![Page 13: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/13.jpg)
NVMO, 19 november 2004
Detectiekans micrometastasen
Metastasis size
0
0,2
0,4
0,6
0,8
1
2 4 6 8 10 12
Number of sections in 2-mm block
pro
ba
bil
ity
of
de
tect
ion 0.5 mm
0.2 mm
LOE
![Page 14: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/14.jpg)
Is een geïsoleerde tumorcel of
micrometastase in de okselklieren
een indicatie voor aanvullende
systeemtherapie?
![Page 15: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/15.jpg)
NVMO, 19 november 2004
CBO Richtlijn Behandeling Mammacarcinoom 2002 / 2004
“Indien in de okselklieren een
micrometastase aanwezig is, wordt
dit voor de prognose beschouwd als
een N0 situatie”
![Page 16: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/16.jpg)
NVMO, 19 november 2004
St Gallen Richtlijn Behandeling Mammacarcinoom 2003
“The new AJCC classification includes
patients with isolated tumor cells in lymph
nodes as having node-negative status. This
may lead to uncertainty about the proper
risk category for such patients.”
![Page 17: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/17.jpg)
NVMO, 19 november 2004
Dilemma in NederlandClassificatie van micrometastase als pN1, maar behandelen als pN0
Dilemma St Gallen Classificatie van geïsoleerde tumorcel als
pN0, maar onzekerheid over het prognostisch risico
![Page 18: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/18.jpg)
NVMO, 19 november 2004
Prognose ‘occulte’ metastasen vs ‘echt’ pN0
Author Method Number H&E N0
Occult (%)
10 jrs DFS, (%)
P *
Friedman SS 456 9 RR 0.59 0.05
Wilkinson SS 525 17 65 vs 71 NS
Hainsworth IHC 343 12 54 vs 84 NS
Trojani IHC 150 14 80 vs 90 NS
Nasser SS + IHC 159 31 51 vs 68 < 0.05
McGuckin SS + IHC 208 25 65 vs 85 NS
Bettelheim* SS 921 9 58 vs 74 0.003
Cote* IHC 736 20 55 vs 63 NS
Tjan-Heijnen et al.
Breast Cancer Res and Treat 2001
![Page 19: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/19.jpg)
NVMO, 19 november 2004
Prognose geïsoleerde cellen micrometastasen
•Cote, 10 jrs DFS:
•IHC 0 cellen: 63%
•IHC 1-100 cellen: 57%
•IHC > 100 cellen: 40% ( > 0.2
mm )
![Page 20: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/20.jpg)
NVMO, 19 november 2004
Prognose geïsoleerde cellen micrometastasen:
Mc Guckin,Br J Cancer 1995
![Page 21: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/21.jpg)
NVMO, 19 november 2004
Take Home Message
Micrometastasen: prognostisch ongunstig,
geïsoleerde tumorcellen mogelijk niet
Niveau 3
pN1 versus pN0
![Page 22: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/22.jpg)
NVMO, 19 november 2004
Take Home Message
Maar…
Onduidelijk of primaire tumorkenmerken
corrigeren voor slechtere prognose bij
aanwezigheid van micrometastasen
Eerlijk is eerlijk
![Page 23: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/23.jpg)
NVMO, 19 november 2004
Regionale ervaring met de SWK procedure
N = 556
CBO 2004:
pN-stadium (SWK + OKD)
pN0(i-)
63%
pN0(i+)
8%
pN1mi
9%
pN1a-c *
20%
Gunstig 69% 62% 56% 38%
Ongunstig 31% * 38% 44% 62%
* Prognostisch onafhankelijke factor
![Page 24: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/24.jpg)
NVMO, 19 november 2004
10.000 patiënten met SWK biopt
2000 pN0(i+) of pN1mi
1.000 pN0(i+) of pN1mi èn ongunstige kenmerken
1.000 pN0(i+) of pN1mi èn gunstige kenmerken
6.000 pN0(i-)
Jaarlijks in NL
![Page 25: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/25.jpg)
NVMO, 19 november 2004
MIRROR-studie (BOOG/ZonMw)
Micro-metastases and
Isolated tumour cells:
Relevant and Robust
or Rubish?
![Page 26: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/26.jpg)
NVMO, 19 november 2004
MIRROR studie
N= 3000 patiënten
met gunstige kenmerken
met SWK in 2002 of eerder
Cohort I
pN0(i-)
Geen systeemtherapie
Cohort II
pN0(i+) of pN1mi
Geen systeemtherapie
Cohort III
pN0(i+) of pN1mi
Wel systeemtherapie
![Page 27: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/27.jpg)
NVMO, 19 november 2004
Regionale ervaring met de SWK procedureWel / geen aanvullende OKD ?
N=556 pt pN0(i+)(sn) pN1mi(sn) pN1a-c (sn)
Positieve
non-SN14.9% 29.2% 36.6%
LOE
![Page 28: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/28.jpg)
NVMO, 19 november 2004
Conclusies
•De definitie: TNM classificatie
•PA protocol: tenminste 3 levels, liever méér, + IHC
•Prognostisch: micrometastasen mogelijk ongunstig
•Adjuvante systeemtherapie: ja, ook bij micrometastase
•Aanvullende OKD: ja, indien SWK tumorcel +
![Page 29: Prevention of chemotherapy-induced FN by AB +/- G-CSF in SCLC: a randomized phase III study](https://reader035.fdocuments.net/reader035/viewer/2022070418/5681587e550346895dc5e12d/html5/thumbnails/29.jpg)
NVMO, 19 november 2004